PR Newswire
London, August 10
Director/PDMR Shareholding
August 10, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transactions by person discharging managerial responsibilities
| 1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA") | |||||
| a) | Name | Perry Sternberg | ||||
| 2. | Reason for the notification | |||||
| a) | Position / status | Head of US Commercial - PDMR | ||||
| b) | Initial notification / amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Shire plc | ||||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares ("ADSs") | ||||
| Identification code | ISIN: US82481R1068 | |||||
| b) | Nature of the transaction | Exercise of Stock Appreciation Rights ("SARs") in respect of notional ADSs awarded under the Shire Portfolio Share Plan and consequent receipt of ADSs. (Details of related disposal of ADSs are referenced in section 5. below.) | ||||
| c) | Price(s) and volume(s) | Exercise price(s) | Volume(s) SARs exercised | Volume(s) ADSs received | ||
| $119.2700 | 1,778 | 712 | ||||
| $168.5400 | 741 | 114 | ||||
| d) | Aggregated information | Weighted average exercise price | Volume SARs exercised | Volume ADSs received | ||
| $133.7635 | 2,519 | 826 | ||||
| e) | Date of the transaction | August 9, 2016 | ||||
| f) | Place of the transaction | N/A | ||||
| 5. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares ("ADSs") | ||||
| Identification code | ISIN: US82481R1068 | |||||
| b) | Nature of the transaction | Disposal of ADSs (Disposal marked with * is in relation to the exercise of SARs referenced in section 4. above. Part of the proceeds of this disposal were used to satisfy personal tax liabilities arising from the exercise of the SARs.) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| $199.2100 | 86 | |||||
| $199.0102 | 404 | |||||
| $198.7140 | 826* | |||||
| d) | Aggregated information | Weighted average price | Volume | |||
| $198.8373 | 1,316 | |||||
| e) | Date of the transaction | August 9, 2016 | ||||
| f) | Place of the transaction | NASDAQ Global Select Market | ||||
For further information please contact:
| Investor Relations | ||
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com
